SequelSEC

Exousia Bio, Inc. LMMY

Services-Educational Services · CIK 0001939937 · Fiscal year ends 0531

AnnualQuarterlyTTM
Revenue
$0
Fiscal year ended 2026-02-28
Operating income
$0
Fiscal year ended 2026-02-28
Free cash flow
$0
Fiscal year ended 2026-02-28

Valuation, from the filing

Public float$1.29MMarket value of stock held by non-affiliates, as stated on the cover page for 2024-11-30
Float per share$0.17Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.
Float / net income25.1×A lower bound on the multiple, because affiliate holdings are excluded.
Float / revenue343.7×A lower bound on the multiple, because affiliate holdings are excluded.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2024-11-30, not today, and each multiple below it uses the figures for the fiscal year ending 2025-05-31 — the year that filing covered.

How this compares in its industry

Percentile among the Services-Educational Services filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
Effective tax rate0.0%0th
Gross margin-93.4%0th
Net margin1370.5%100th
Revenue YoY growth-67.4%0th

Exousia Bio, Inc. (LMMY) reported revenue of $0 and net income of $0 for the fiscal year ended 2026-02-28. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from Exousia Bio, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Services-Educational Services.

Income

Exousia Bio, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-02-282025-11-302025-08-312025-05-312025-02-282024-11-302024-08-312024-05-312024-02-292023-11-30
Revenue$0$0$0$0$0$0$3.75K$3.75K$3.88K$3.88K
Cost of revenue$0$62.11K$0$7.25K$0$0$0UnavailableUnavailableUnavailable
Gross profit$0-$62.11K$0-$7.25K$0$0$3.75K-$5.92K$3.88K$3.88K
Operating income$0-$237.00K-$31.81KUnavailable$0$6.98K-$4.34KUnavailable-$8.70K-$7.45K
Net income$0-$19.08K-$31.81K-$29.26K$61.83K$80.13K-$3.91K-$5.25K-$4.82K-$3.57K
Research & developmentUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Weighted-average diluted sharesUnavailableshares 16.76Mshares 7.78MUnavailableUnavailableshares 7.78Mshares 7.78MUnavailableshares 7.78Mshares 7.00M
Pretax income$0-$19.08K-$31.81K-$29.26K$61.88K$80.13K-$3.91K-$5.25K-$4.82K-$3.57K
Income tax expense$0$0$0$0$0$0$0$0$0$0
Diluted EPSUnavailable$0.00$0.00UnavailableUnavailable$0.01$0.00Unavailable$0.00$0.00
Selling, general & administrativeUnavailable$0UnavailableUnavailableUnavailable$6.98KUnavailableUnavailableUnavailableUnavailable
General & administrativeUnavailableUnavailableUnavailable$17.75K$23.83K$6.98K$8.09K-$228$8.70K$7.45K
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

Exousia Bio, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-02-282025-11-302025-08-312025-05-312025-02-282024-11-302024-08-312024-05-312024-02-292023-11-30
Cash & equivalentsUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Total assets$22.05M$22.05M$0$0$0$24.85K$27.96K$27.45K$26.94K$26.74K
Current assets$0$0$0$0$0$17.72K$17.14K$12.96K$8.78K$4.90K
Total liabilities$261.02K$261.02K$35.31K$0$0$0$86.76K$82.35K$76.58K$71.56K
Current liabilities$261.02K$261.02K$35.31K$0$0$0$17.17K$14.17K$9.82K$6.21K
Total equity incl. NCI$21.79M$21.79M-$35.31K$0$24.85K$24.85K-$58.80K-$54.90K-$49.64K-$44.82K
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
InventoryUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivable$0$0$0$0$0$15.25K$15.25K$11.50K$7.75K$3.88K
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payable$212.30K$212.30KUnavailable$0UnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Cash flow

Exousia Bio, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-02-282025-11-302025-08-312025-05-312025-02-282024-11-302024-08-312024-05-312024-02-292023-11-30
Operating cash flow$0$173.13K$3.50K-$91.07K$0$90.21K-$3.68K-$1.41K-$1.42K-$1.70K
Capital expenditures$0UnavailableUnavailableUnavailable$0UnavailableUnavailableUnavailableUnavailableUnavailable
Investing cash flow$0-$22.05M$0$0$0-$3.68K$3.68K$0$0$0
Financing cash flow$0$21.88M-$3.50K$90.04K$0-$86.54K$0$1.42K$1.41K$1.41K
Net change in cashUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Stock-based compensationUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortizationUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Derived

Exousia Bio, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-02-282025-11-302025-08-312025-05-312025-02-282024-11-302024-08-312024-05-312024-02-292023-11-30
Free cash flow$0UnavailableUnavailableUnavailable$0UnavailableUnavailableUnavailableUnavailableUnavailable
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable100.0%-157.8%100.0%100.0%
Operating marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable-115.8%UnavailableUnavailableUnavailable
FCF marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
SBC / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Current ratio0.00x0.00x0.00xUnavailableUnavailableUnavailable1.00x0.91x0.89x0.79x
Revenue YoY growthUnavailableUnavailable-100.0%-100.0%-100.0%-100.0%UnavailableUnavailableUnavailableUnavailable
Net marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable-104.3%-140.1%-124.4%-92.2%
R&D / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
CapEx / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailable0.0%0.0%UnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open LMMY in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-06-16View SEC filing
10-Q · Filed 2026-03-17View SEC filing
10-Q · Filed 2025-11-17View SEC filing
10-K · Filed 2025-10-17View SEC filing
10-Q · Filed 2025-04-24View SEC filing
10-Q · Filed 2025-01-10View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.